EUVIMEDEUVIMED entdecken
Crossref

Inhibiting Neuropilin-1 as a novel therapeutic approach to mitigate pulmonary fibrosis: Highlighting the potential anti-fibrotic effects of ATWLPPR peptide

Gauthami Pulivendala, Swarna Bale, Sai Kiran Yanala, Rajendra Sangaraju, Chandraiah Godugu

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Gauthami Pulivendala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad,…. Hauptthemen laut MEDLINE: Neuropilin-1, Pulmonary Fibrosis, Oligopeptides, Antifibrotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Latent transforming growth factor 1 (TGF-β1) is present in substantial quantities in healthy tissues. The regulation of TGF-β1 under fibrotic conditions predominantly relies on mechanisms that activate latent TGF-β1 to its active/mature form rather than its secretion and synthesis. Consequently, one strategy for mitigating pulmonary fibrosis involves targeting activation of the master cytokine TGF-β1 from its latent form. Recent evidence suggests Neuropilin-1 (NRP-1) is an activator of TGF-β1 with significant biological functions, including acting as a co-receptor for TGF-β1 and facilitating divergent Smad signaling in favor of fibrogenesis. In the present study, we conducted an initial preclinical investigation to validate NRP-1 as a potential target in fibrosis, utilizing a specific NRP-1 inhibitor, ATWLPPR (A7R). A7R is a heptapeptide that specifically binds to NRP-1 to inhibit its activity. This study was performed using a 21-day model of bleomycin-induced pulmonary fibrosis in Swiss Albino mice. Our results demonstrated that the inhibition of NRP-1 by A7R exhibited promising anti-fibrotic activity. We found that A7R downregulated the expression of epithelial-mesenchymal transition proteins. A7R demonstrated significant potential to attenuate the expression of TGF-β1 and its downstream Smad signaling through substantial inhibition of NRP-1. Additionally, we observed a reduction in collagen deposition after A7R treatment. Notably, the anti-fibrotic effect of A7R was comparable to that of pirfenidone. In conclusion, our study demonstrated that the NRP-1 specific inhibitor A7R, exhibits considerable potential to attenuate pulmonary fibrosis, although further comprehensive investigations are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuropilin-1Pulmonary FibrosisOligopeptidesAntifibrotic AgentsAnimalsMiceTransforming Growth Factor beta1BleomycinLungMaleHumansDisease Models, AnimalEpithelial-Mesenchymal TransitionSignal Transduction

Stichwörter der Autor:innen

A7R (ATWLPPR) peptideBleomycinNeuropilin-1Pulmonary fibrosisTransforming growth factor 1

Substanzen

Neuropilin-1Transforming Growth Factor beta1BleomycinOligopeptidesAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana State 500037, India.
  • Department of Biological Sciences (Regulatory Toxicology), National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana State 500037, India. Electronic address: chandra.niperhyd@g…

Förderung

  • Department of Science and Technology

Zitieren

APA

Pulivendala, G., Bale, S., Yanala, S. K., Sangaraju, R., & Godugu, C. (2025). Inhibiting Neuropilin-1 as a novel therapeutic approach to mitigate pulmonary fibrosis: Highlighting the potential anti-fibrotic effects of ATWLPPR peptide. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114757

Vancouver

Pulivendala G, Bale S, Yanala SK, Sangaraju R, Godugu C. Inhibiting Neuropilin-1 as a novel therapeutic approach to mitigate pulmonary fibrosis: Highlighting the potential anti-fibrotic effects of ATWLPPR peptide. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114757

BibTeX
@article{Pulivendala2025,
  author = {Pulivendala, Gauthami and Bale, Swarna and Yanala, Sai Kiran and Sangaraju, Rajendra and Godugu, Chandraiah},
  title = {Inhibiting Neuropilin-1 as a novel therapeutic approach to mitigate pulmonary fibrosis: Highlighting the potential anti-fibrotic effects of ATWLPPR peptide},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114757}
}
Kostenlos starten →